VVOS
Vivos Therapeutics, Inc.
$0.5720
-6.84%
$7.9M
No data for this timeframe.
Vol
Market Cap$7.9M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (78%)
Inst. Holders9 funds
Inst. Value$471.3K
Inst. Activity1 buys / 1 sells
Insider Activity4B / 0S
Insider Net $$6.8M
SEC Reports6
Press Releases1
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001716166·Prev Close $0.6140
Recent Activity
Jun 11, 2026
activist
Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering
Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering
Jun 8, 2026
SEC
Vivos Therapeutics disclosed a delisting notice from Nasdaq for failing to maintain a $1.00 minimum bid price, alongside
8-K — Impact 7/10
May 20, 2026
SEC
Vivos Therapeutics reported Q1 2026 revenue of $5.14M (+70% YoY, 19.6% above consensus) but EPS of -$0.52 missed estimat
PRESS-RELEASE — Impact 5/10
Apr 15, 2026
SEC
Vivos Therapeutics reported full-year 2025 revenue of $17.4 million, a 16% year-over-year increase driven by the integra
8-K — Impact 6/10
Mar 31, 2026
Insider
Skaff Michael C bought 429,957 shares
10%+ Owner @ $1.34 ($576.1K)
Mar 31, 2026
Insider
Skaff Michael C bought 1,044,777 shares
10%+ Owner @ $1.34 ($1.4M)
Mar 31, 2026
Insider
Skaff Michael C bought 1,783,582 shares
10%+ Owner @ $1.34 ($2.4M)
Inst.
VANGUARD GROUP INC — DOUBLED
304,161 shares ($617.4K)
Price Targets
$2.45
+328.3% upside
Strong Buy
Current $0.5720
Low $1.75
Median $2.50
High $3.10
3 analysts
$1.75
$3.10
Analyst Ratings
2Strong Buy
5Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 4, 2026 | Ascendiant Capital | MAINTAIN | Buy → Buy |
| Apr 22, 2026 | Ascendiant Capital | MAINTAIN | Buy → Buy |
| Apr 17, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.47 ▼ -51.6% | $-0.54 — $-0.40 | 15% YoY | 2 |
| Next Q | $-0.42 ▼ -65.8% | $-0.54 — $-0.30 | 14% YoY | 2 |
| Current FY | $-1.82 ▼ -57.8% | $-2.14 — $-1.50 | 12% YoY | 2 |
| Next FY | $-0.84 ▼ -140.0% | $-2.17 — $0.00 | 54% YoY | 3 |
Latest Reports
BEARISH
8-K
7/10
Vivos Therapeutics disclosed a delisting notice from Nasdaq for failing to maintain a $1.00 minimum bid price, alongside
Jun 8, 2026
MIXED
PRESS-RELEASE
5/10
Vivos Therapeutics reported Q1 2026 revenue of $5.14M (+70% YoY, 19.6% above consensus) but EPS of -$0.52 missed estimat
May 20, 2026
NEUTRAL
Press
5/10
Vivos Therapeutics closed a $2.25 million private placement with V-Co Investors 3 LLC, an affiliate of New Seneca Partne
Apr 7, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | NEAR_EXIT |
| VANGUARD CAPITAL MANAGEMENT LLC | $322.5K | — |
| COMMONWEALTH EQUITY SERVICES, LLC | $50.1K | ADD |
| VANGUARD FIDUCIARY TRUST CO | $36.4K | — |
| BlackRock, Inc. | $32.8K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 31, 2026 | Skaff Michael | BUY | $576.1K |
| Mar 31, 2026 | Skaff Michael | BUY | $1.4M |
| Mar 31, 2026 | Skaff Michael | BUY | $2.4M |
| Mar 31, 2026 | Skaff Michael | BUY | $2.4M |
9 institutional holders with $471.3K total value (399,415 shares) as of 2026-Q1. Top holders: ROYAL, VANGUARD, COMMONWEALTH.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 4 | $0.00 | 0.0% | NEAR_EXIT -100.0% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 273,329 | $322.5K | 68.4% | — |
| 3 | COMMONWEALTH EQUITY SERVICES, LLC | 42,500 | $50.1K | 10.6% | ADD +30.8% |
| 4 | VANGUARD FIDUCIARY TRUST CO | 30,832 | $36.4K | 7.7% | — |
| 5 | BlackRock, Inc. | 27,817 | $32.8K | 7.0% | — |
| 6 | STATE STREET CORP | 24,922 | $29.4K | 6.2% | DOUBLED +110.8% |
| 7 | MORGAN STANLEY | 7 | $8.00 | 0.0% | NEAR_EXIT -99.3% |
| 8 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 3 | $4.00 | 0.0% | — |
| 9 | CITIGROUP INC | 1 | $1.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | DOUBLED | 91,461 | 304,161 | +232.6% | $617.4K | 2025-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 1,065 | 7 | -99.3% | $14.00 | 2025-Q4 |
| VANGUARD GROUP INC | DOUBLED | 42,634 | 91,461 | +114.5% | $283.5K | 2025-Q3 |
| STATE STREET CORP | DOUBLED | 11,822 | 24,922 | +110.8% | $77.3K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 142,801 | 102 | -99.9% | $316.00 | 2025-Q3 |
| ROYAL BANK OF CANADA | NEAR_EXIT | 18,004 | 4 | -100.0% | — | 2025-Q2 |
| UBS Group AG | DOUBLED | 1,879 | 142,801 | +7499.8% | $451.3K | 2025-Q2 |
| ROYAL BANK OF CANADA | DOUBLED | 4 | 18,004 | +450000.0% | $51.0K | 2025-Q1 |
| UBS Group AG | DOUBLED | 389 | 1,879 | +383.0% | $5.4K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 74 | 1,314 | +1675.7% | $3.7K | 2025-Q1 |
| COMMONWEALTH EQUITY SERVICES, LLC | ADD | 26,000 | 34,000 | +30.8% | $97.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 78 | 389 | +398.7% | $1.7K | 2024-Q4 |
| ROYAL BANK OF CANADA | TRIM | 7 | 4 | -42.9% | — | 2024-Q3 |
| COMMONWEALTH EQUITY SERVICES, LLC | ADD | 16,000 | 21,000 | +31.3% | $55.00 | 2024-Q3 |
1 unique insiders with 4 transactions. Net insider value: $6.8M ($6.8M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | Skaff Michael C | 10%+ Owner | BUY | 429,957 | $1.34 | $576.1K |
| Mar 31, 2026 | Skaff Michael C | 10%+ Owner | BUY | 1,044,777 | $1.34 | $1.4M |
| Mar 31, 2026 | Skaff Michael C | 10%+ Owner | BUY | 1,783,582 | $1.34 | $2.4M |
| Mar 31, 2026 | Skaff Michael C | 10%+ Owner | BUY | 1,783,582 | $1.34 | $2.4M |
6 SEC filing reports analyzed. Sentiment: 0 bullish, 4 bearish, 2 mixed, 0 neutral. Avg impact: 6.2/10.
BEARISH
8-K
7/10
Vivos Therapeutics disclosed a delisting notice from Nasdaq for failing to maintain a $1.00 minimum
Jun 8, 2026
MIXED
PRESS-RELEASE
5/10
Vivos Therapeutics reported Q1 2026 revenue of $5.14M (+70% YoY, 19.6% above consensus) but EPS of -
May 20, 2026
MIXED
8-K
6/10
Vivos Therapeutics reported full-year 2025 revenue of $17.4 million, a 16% year-over-year increase d
Apr 15, 2026
BEARISH
PRESS-RELEASE
6/10
Vivos Therapeutics reported full-year 2025 revenue of $17.4 million, up 16% YoY, driven by sleep tes
Apr 15, 2026
BEARISH
PRESS-RELEASE
6/10
Vivos Therapeutics (VVOS) reported Q3 2025 earnings with EPS of -$0.49, missing consensus by 1.4%, o
Apr 15, 2026
BEARISH
8-K
7/10
Vivos Therapeutics raised $2.39 million through a private placement with existing backer V-Co Invest
Apr 3, 2026
Current analyst consensus: Buy (78% buy). Based on 9 analysts: 2 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$2.45 mean target
+328.3% upside
Strong Buy (1.67)
$1.75 Low
$3.10 High
| Metric | Value |
|---|---|
| Current Price | $0.5720 |
| Target Low | $1.75 |
| Target Mean | $2.45 |
| Target Median | $2.50 |
| Target High | $3.10 |
| # Analysts | 3 |
| Recommendation | Strong Buy (1.67) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.47 | $-0.54 | $-0.40 | 14.5% | -51.6% | 0↑ 1↓ | $0.0B | 47.9% | 2 |
| Next Q 2026-09-30 |
$-0.42 | $-0.54 | $-0.30 | 14.3% | -65.8% | 0↑ 1↓ | $0.0B | -14.5% | 2 |
| Current FY 2026-12-31 |
$-1.82 | $-2.14 | $-1.50 | 12.1% | -57.8% | 0↑ 1↓ | $0.0B | 32.5% | 2 |
| Next FY 2027-12-31 |
$-0.84 | $-2.17 | $0.00 | 53.8% | -140.0% | — | $0.0B | 49.3% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.470 | |
| 7d ago | $-0.400 | -0.070 |
| 30d ago | $-0.310 | -0.160 |
| 60d ago | $-0.375 | -0.095 |
| 90d ago | $-0.375 | -0.095 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 4, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
| Apr 22, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
| Apr 17, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| May 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Apr 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Mar 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Feb 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Jan 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
Recent Reddit Threads
Potentially Vivos (Nasdaq:VVOS) 40 million naked short
▲ 1
💬 0
⚡ 0.5
Jun 11, 2026
activist
Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering
Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering
Jun 10, 2026
contract
Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients
Vivos Announces Collaboration Agreement with Florida Cardiology Group to Extend Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Pat
Jun 8, 2026
other
Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026
Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026
Jun 5, 2026
other
Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing
Vivos Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq List
May 20, 2026
earnings
Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update
Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update
May 13, 2026
earnings_calendar
VVOS Q1 2026 Earnings Scheduled — 2026-05-13
Apr 16, 2026
short_volume
Short Volume: VVOS — 64.1% short (0.4M / 0.6M)
Short: 362,984 | Exempt: 38,243 | TRF Vol: 566,217 | Short Ratio: 64.1% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
earnings
Vivos Therapeutics Reports Full Year 2025 Financial Results
Vivos Therapeutics Reports Full Year 2025 Financial Results
Full Year 2025 revenue increased 16%
Apr 15, 2026
earnings
Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call
Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call
Apr 7, 2026
offering
Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners
Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners
Mar 30, 2026
earnings_calendar
VVOS Q4 2025 Earnings After Market Close — 2026-03-30
Mar 26, 2026
other
Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market
Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medi
Mar 17, 2026
other
Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy
Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy